<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03710122</url>
  </required_header>
  <id_info>
    <org_study_id>IND133287</org_study_id>
    <secondary_id>FD-R-6102</secondary_id>
    <nct_id>NCT03710122</nct_id>
  </id_info>
  <brief_title>Vancomycin for Primary Sclerosing Cholangitis</brief_title>
  <official_title>A Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vanycomycin in Adults With Primary Sclerosing Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elizabeth Carey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arizona State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find out if vancomycin is a safe and effective therapy for primary sclerosing cholangitis.&#xD;
&#xD;
      Funding Source - FDA OOPD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A. Determine if OV normalizes serum ALP in adults with PSC. Levels of serum ALP obtained at&#xD;
      6,12,and 18 months of OV treatment, and at 3, and 6 months post OV treatment will be compared&#xD;
      to those obtained at baseline (month 0), and with values at the same study time points in the&#xD;
      placebo arm.&#xD;
&#xD;
      B. Determine if OV stabilizes or improves liver fibrosis assessed by LSM using TE. Liver&#xD;
      stiffness will be measured at 6, 12, and 18 months of OV treatment, and at 6 months post OV&#xD;
      treatment, and values will be compared to those obtained at baseline (month 0), and with&#xD;
      values in the placebo arm.&#xD;
&#xD;
      C. Determine the changes in the intestinal microbiota in relation to the use of OV, and study&#xD;
      the correlation between the changes in the intestinal microbiota and the changes in: 1) liver&#xD;
      enzymes, particularly serum ALP, and 2) liver stiffness, assessed by LSM using TE.&#xD;
&#xD;
      D. Determine if changes in proinflammatory cytokines (TGF-β, IL-4, IL-13, IL-10, etc.)&#xD;
      predict response to OV. Cytokines will be measured at baseline, months 6, 12, 18, and at 3,&#xD;
      and 6 months post OV treatment, if the study is positive.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alkaline phosphatase at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Determine if OV normalizes serum ALP in adults with PSC. Levels of serum ALP obtained at 6 months of OV treatment, and will be compared to those obtained at baseline (month 0), and with values at the same study time points in the placebo arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alkaline phosphatase at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Determine if OV normalizes serum ALP in adults with PSC. Levels of serum ALP obtained at 12 months of OV treatment, and will be compared to those obtained at baseline (month 0), and with values at the same study time points in the placebo arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alkaline phosphatase at 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>Determine if OV normalizes serum ALP in adults with PSC. Levels of serum ALP obtained at 18 months of OV treatment, and will be compared to those obtained at baseline (month 0), and with values at the same study time points in the placebo arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alkaline phosphatase at 3 months post treatment = 21 months</measure>
    <time_frame>21 months</time_frame>
    <description>Determine if OV normalizes serum ALP in adults with PSC. Levels of serum ALP obtained at 3 months post OV treatment, and will be compared to those obtained at baseline (month 0), and with values at the same study time points in the placebo arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alkaline phosphatase at 6 months post treatment = 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Determine if OV normalizes serum ALP in adults with PSC. Levels of serum ALP obtained at 6 months post OV treatment, and will be compared to those obtained at baseline (month 0), and with values at the same study time points in the placebo arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibroscan, cholangiography</measure>
    <time_frame>18 months</time_frame>
    <description>Transient elastography (TE), a new technique that allows non-invasive assessment and follow up of liver fibrosis by measuring liver stiffness, differentiates between severe from non-severe fibrosis in PSC, and the rate of progression of liver stiffness measurement (LSM) assessed by TE correlates well with the rate of progression of fibrosis in PSC and with patients' clinical outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Firvanq by Cutis Pharma</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for Vancomycin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subject age 18-75 years&#xD;
&#xD;
          2. Diagnosis of PSC consistent with the guidelines published by the American Association&#xD;
             for the Study of Liver Diseases (AASLD). All subjects must have an elevated serum ALP&#xD;
             of at least 1.5 times upper limit of normal at baseline plus cholangiographic evidence&#xD;
             of PSC, as demonstrated by magnetic resonance imaging, endoscopic retrograde&#xD;
             cholangiography, direct cholangiography or liver biopsy.&#xD;
&#xD;
          3. An ultrasound (or equivalent imaging modality) that excludes biliary obstruction and&#xD;
             malignancy within 6 months of study entry.&#xD;
&#xD;
          4. If a patient is on any of the following medications and/or supplements, he or she is&#xD;
             expected to remain on the same daily dose through the treatment period: UDCA,&#xD;
             azathioprine, prednisone (or an equivalent steroid compound), methotrexate, a&#xD;
             5-aminosalicylic acid, biologic therapy, and/or a probiotic.&#xD;
&#xD;
          5. PSC with or without inflammatory bowel disease, such as ulcerative colitis or Crohn's&#xD;
             disease.&#xD;
&#xD;
          6. Must agree to comply with the study protocol and provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Administration of an antibiotic within 3 months prior to the study 2. Pregnancy or&#xD;
        attempting to become pregnant or breastfeeding 3. Presence of any of the following:&#xD;
&#xD;
          1. Hepatitis B infection&#xD;
&#xD;
          2. Hepatitis C infection (antibody positive); patients with a history of hepatitis C&#xD;
             infection will be eligible for this study if they have undetectable levels of HCV RNA&#xD;
&#xD;
          3. Other cholestatic liver diseases such as primary biliary cholangitis and cholestatic&#xD;
             diseases of pregnancy&#xD;
&#xD;
          4. Metabolic liver diseases such as Wilson's disease and hemochromatosis&#xD;
&#xD;
          5. Inherited diseases of the liver such as α-1 antitrypsin deficiency&#xD;
&#xD;
          6. Immunoglobulin G4-related cholangitis&#xD;
&#xD;
          7. PSC with concomitant autoimmune hepatitis (AIH) &amp;/or primary biliary cholangitis&#xD;
             (previously known as primary biliary cirrhosis)&#xD;
&#xD;
          8. Secondary sclerosing cholangitis (SSC)&#xD;
&#xD;
          9. Active acute ascending cholangitis requiring antibiotics&#xD;
&#xD;
         10. CCA (malignant biliary stricture, neoplasm, &amp; cytology/histopathology or positive&#xD;
             fluorescence in situ hybridization (FISH) consistent with adenocarcinoma of the bile&#xD;
             duct)&#xD;
&#xD;
         11. A liver biopsy, if one has been previously obtained, which showed non-alcoholic&#xD;
             steatohepatitis (NASH). Patients with suspected fatty liver imaging will not be&#xD;
             excluded&#xD;
&#xD;
         12. Presence of complications of advanced PSC such as hepatic encephalopathy, portal&#xD;
             hypertension, hepato-renal syndrome and hepato-pulmonary syndrome&#xD;
&#xD;
         13. History of liver transplantation, anticipated need for liver transplantation within 12&#xD;
             months from randomization, or a Model of End Stage Liver Disease (MELD) score of ≥15&#xD;
&#xD;
         14. Ongoing alcohol abuse (&gt;4 drinks per day for men, and &gt;2 drinks per day for women)&#xD;
&#xD;
         15. History of allergic reaction to vancomycin&#xD;
&#xD;
         16. Moderate-to-severe renal impairment with a calculated creatinine clearance of&#xD;
             &lt;60mL/min&#xD;
&#xD;
        r. HIV/AIDS q. Any other conditions or abnormalities that, in that opinion of the&#xD;
        investigator, may compromise the safety of the subject or interfere with the subject&#xD;
        participating in or completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Carey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saran Vaughn</last_name>
    <phone>408-342-6487</phone>
    <email>Vaughn.Saran@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Carey, MD</last_name>
      <phone>480-342-1094</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona State University</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise M Harnois, DO</last_name>
      <phone>904-956-3258</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Eaton, MD</last_name>
      <phone>507-284-3917</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Elizabeth Carey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

